A Randomized, Double-blind, Multicentre, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses | MicrobiomeTrials
A Randomized, Double-blind, Multicentre, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-05-01Est. Completion: 2027-08-01
Enrollment target: 96 participants
Locations
University Clinical Hospital Mostar, Clinic for Infectious Diseases, Mostar, Herzegovina-Neretva Canton, Bosnia and Herzegovina
University Clinical Center Republic of Srpska, Clinic for Infectious Diseases, Banja Luka, Republika Srpska, Bosnia and Herzegovina
University Clinical Centre Sarajevo, Clinic for Infectious Diseases, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina
Clinical Center of Montenegro, Clinic for Infectious Diseases, Podgorica, Podgorica Municipality, Montenegro
Te Toka Tumai Auckland, Auckland City Hospital, Auckland, New Zealand
Aotearoa Clinical Trial Trust, Esme Green Building, Middlemore Hospital, Auckland, New Zealand
Christchurch Hospital, 2 Riccarton Avenue,, Christchurch, New Zealand
MRINZ, 7 CSB Building, Wellington Hospital, Wellington, New Zealand
University Clinical Centre Nis, Clinic for Infectious Diseases, Niš, Nišava District, Serbia
Health Center Uzice, General Hospital Uzice, Užice, Zlatibor District, Serbia
University Clinical Centre of Serbia, Clinic for Infectious Diseases, Belgrade, Serbia
Other microbiome trials you might be interested in